Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495895 | 0.94 | PDK1 (0.42) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL618279 | 0.85 | PDK1 (0.49) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL4402755 | 0.85 | PDK1 (0.49) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL16415404 | 0.85 | PDK1 (0.49) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL12527484 | 0.80 | KMT2A (0.43) | PDK1KMT2AMEN1 | |
| SCHEMBL23396268 | 0.79 | GAA (0.39) | PDK1ALDH1A1L3MBTL1ALOX12NPC1 | |
| SCHEMBL31494035 | 0.78 | EPHA2 (0.42) | PDK1KMT2AMEN1 | |
| SCHEMBL29186133 | 0.78 | ALDH1A1 (0.44) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL28131900 | 0.78 | ALDH1A1 (0.44) | PDK1ALDH1A1L3MBTL1ALOX12KMT2A | |
| SCHEMBL19437270 | 0.75 | PDK1 (0.39) | PDK1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4121422-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | PDK1 1366/4885ALDH1A1 3531/4885L3MBTL1 243/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | PDK1 1366/4885ALDH1A1 3531/4885L3MBTL1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.